Jiwan Qiu
GM & Chairman of the BoardMr. Jiwan Qiu is the Founder of Qyuns Therapeutics Co., Ltd. and its subsidiaries. He was appointed as Qyuns Therapeutics Co., Ltd.’s Director on June 5, 2015 and was re-designated as Qyuns Therapeutics Co., Ltd.’s Executive Director on March 23, 2023. Mr. Qiu was Qyuns Therapeutics Co., Ltd.’s Chief Executive Officer since June 2015 and serves as the General Manager since September 2021 and is the Chairman of our Board since February 2022. Mr. Qiu also holds various Directorships and management positions in Qyuns Therapeutics Co., Ltd. and its subsidiaries, including (i) the Executive Director of Saifu Juli since July 2018, where he has been primarily responsible for the overall management of Saifu Juli; and (ii) the General Manager of Cellularforce from August 2018 to March 2023, where he was primarily responsible for the overall management of Cellularforce. As an industry veteran, Mr. Qiu has is experienced in the biotechnology and pharmaceutical industries, where he started as a biotechnology specialist, gradually extended his role as a leader supervising the discovery, technology and manufacturing platform and accumulated management experience in the R&D and manufacturing of biotech companies and eventually became a serial entrepreneur with various entrepreneurial achievements. From July 1993 to January 2004, Mr. Qiu served at Hangzhou Jiuyuan Gene Engineering Co., Ltd., a biotech company primarily engaged in the production of injections and active pharmaceutical ingredients (APIs), with his last position being a Director of research institute, where he was primarily responsible for new drug development. From February 2004 to June 2005, Mr. Qiu served as a Deputy General Manager at Epitomics (Hangzhou) Biotechnology Co., Ltd. (“Hangzhou Epitomics”), a biotech company primarily engaged in the R&D and manufacturing of antibody reagents, where he was primarily responsible for the establishment of the production and technology platform. From December 2005 to January 2015, Mr. Qiu founded Jiangsu T-mab BioPharma Co., Ltd. (“Jiangsu T-mab”) and its two subsidiaries,Hangzhou Genewave Biotechnology Co., Ltd. (“Hangzhou Genewave”) and Taizhou Beijin Biotechnology Co., Ltd. (“Taizhou Beijin”), all being companies Principally engaged in the R&D and production of genetically engineered drugs, where Mr. Qiu served as (i) the General Manager at Hangzhou Genewave beginning from December 2005; (ii) the General Manager at Taizhou Beijin beginning from June 2007; and (iii) the General Manager at Jiangsu T-mab from July 2008 to January 2015, primarily responsible for their overall operations and management. Mr. Qiu graduated from Fudan University in the PRC in July 1993 with a bachelor’s degree in genetics and genetic engineering. He also obtained a master’s degree in business administration (MBA) from Zhejiang University in the PRC in June 2005. Mr. Qiu was awarded the Third Prize of Zhejiang Province Science and Technology Award by the People’s Government of Zhejiang Province in 2005 and the Second Prize of Hangzhou Science and Technology Progress Award by Hangzhou Municipal People’s Government in February 2006.
Positions
- Company NameQyuns Therapeutics Co., Ltd.Stock Code02509PositionGM & Chairman of the Board
